Laetitia Debernard1, Tracy R. Melzer1, Saskia Van Stockum1, Jane Eagle1, Charlotte Graham1, Daniel Myall1, Claudia Angela M. Wheeler-Kingshott2, John C. Dalrymple-Alford1, David H. Miller1, 2, Deborah F. Mason1
1New Zealand Brain Research Institute, Christchurch, Canterbury, New Zealand; 2NMR Research Unit, Queen Square MS Centre, UCL Institute of Neurology, London, United Kingdom
Magnetic Resonance Imaging (MRI) is the clinical gold standard to diagnose Multiple Sclerosis (MS). Robust early prognostic markers are needed to accurately follow MS disease. The objective of this study is 1) to investigate grey matter (GM) atrophy and perfusion abnormalities in early relapsing-remitting MS patients, and 2) to correlate these findings with clinical and cognitive impairments. The coupling of both imaging modalities in the same patient sample will enable a more complete description of early pathological mechanisms in MS disease.